Komori
ASKA Pharmaceutical Holdings (4886) · InitiativeAdvancedLatest Earnings presentation (2026-08-04): "Restated"

Phase I/II Trial of AKP-022 (Relugolix Combination Product)

First written in FY2024. 3 of 5 entries say "Advanced", first in 2026-05-11. Latest entry: 2026-08-04.

5entries
3years
3from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY20242024: 120242025: 020252026: 42026
Same theme, other companies
Clinical development of AKP-022 (relugolix combination drug) through Phases I/II and IIIA theme 1 companies write about · 0 as a headwind · 1 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  2. FY2026AdvancedAnnual report

    「子宮内膜症を適応症として開発中のAKP-022（レルゴリクス配合剤）は2025年６月からPhaseⅢ試験を開始しております。」

    AKP-022は2023年7月開始のPhaseⅠ/Ⅱ試験から、2025年6月のPhaseⅢ試験開始へ進展した。
  3. 2026-05-11AdvancedEarnings presentation

    「AKP-022 (relugolix combination product) Uterine fibroids Ph III ongoing AKP-022 (relugolix combination product) Endometriosis Ph III ongoing」

    For AKP-022, Phase III trials are ongoing for both uterine fibroids and endometriosis, an advance from the previous Phase I/II stage.
  4. FY2024First statedAnnual report

    「AKP-022（レルゴリクス配合剤）は2023年7月からPhaseⅠ/Ⅱ試験を開始しました。」

    Relugolix配合剤AKP-022について、2023年7月からPhaseⅠ/Ⅱ試験を開始した。
Moved together

"FY2025 Sales and Profitability Targets and the Vision of a Total Healthcare Company" moved the same way as this thread, in the same document, in 2 of its 5 moves.

222222★123456
  1. ★This thread
  2. 1FY2025 Sales and Profitability Targets and the Vision of a Total Healthcare Company2×
  3. 2Revenue and Profit Growth in the Pharmaceuticals Business2×
  4. 3Addition of Overseas Business as a Reportable Segment2×
  5. 4Launch of the Dysmenorrhea Treatment DroEthi2×
  6. 5Full-Year Revenue and Profit Growth in the Animal Health Business2×
  7. 6Joint Development and Commercialization of an Irritable Bowel Syndrome Treatment App With MICIN2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
ASKA Pharmaceutical Holdings's next results are scheduled for 2026-11-04. Read the earnings preview It last moved in the Earnings presentation of 2026-08-04: "Restated".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.